Showing results (1461-1470 of 1,708) with videos related to

Sort By:
Pageof 171
Heart Rhythm|January 9, 2026
Can Oral Anticoagulants Be Safely Discontinued Following Atrial Fibrillation Ablation? A Systematic Review and Meta-Analysis of Reconstructed Time-to-Event DataLucas M Barbosa, Vinícius Martins Rodrigues Oliveira, André Rivera, et al.
American Heart Journal|June 5, 2017
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trialFreddy Abnousi, Vandana Sundaram, Celina M Yong, et al.
Diabetes Care|September 18, 2021
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With DiabetesDavid D Berg, Stephen D Wiviott, Benjamin M Scirica, et al.
Diabetes, Obesity & Metabolism|August 27, 2020
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
JAMA Cardiology|July 21, 2017
Comparative Outcomes After Percutaneous Coronary Intervention Among Black and White Patients Treated at US Veterans Affairs HospitalsTaisei Kobayashi, Thomas J Glorioso, Ehrin J Armstrong, et al.
JAMA|April 5, 2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trialSteven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Thrombosis Research|July 21, 2020
Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysisAntonia Sambola, Pau Rello, Toni Soriano, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 28, 2023
The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US PerspectiveAndre Lamy, John Eikelboom, Wesley Tong, et al.
JAMA|September 1, 2010
Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosisDeepak L Bhatt, Kim A Eagle, E Magnus Ohman, et al.
Journal of Clinical Lipidology|September 24, 2022
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromesPatrick M Moriarty, Philippe Gabriel Steg, Jennifer McGinniss, et al.
Pageof 171